A leading European magazine, Pharmaceutical Marketing Europe, has turned to Oxford PharmaGenesis to update European pharmaceutical executives on how to plan and run advisory board meetings in the digital age.
The article ‘A rough guide to … advisory boards’ (http://www.pmlive.com/pharma_intelligence/a_rough_guide_to…_advisory_boards_951949) was authored by Chris Winchester, Managing Director of Oxford PharmaGenesis, alongside Trevor Sills, who leads medical communications for the Australian agency Allori, and Helen Leask, founder and head of facilitation practice at the Canadian agency SCRIPT, and showcases the expertise of the companies and their partners in Canada and Australia.
As well as detailing the dos and don’ts of running an advisory board meeting, the article outlines the ten steps to advisory board Shangri-La, based on insights from professional negotiators and UN facilitators. It also shows how technology can be made part of the ad board mix. Planning advisory boards in the same way that publications are planned offers tremendous potential to improve outcomes for participants and sponsors alike. In addition, the article gives advice on important practicalities, such as how to design an advisory meeting so that experts will want to take part.
Chris Winchester explains: “At Oxford PharmaGenesis, we work with specialist partners around the world to deliver thoughtful and impactful advisory board meetings. Between us, Oxford PharmaGenesis, Allori and SCRIPT have organized over 200 advisory board meetings across the globe.”
Oxford PharmaGenesis has a strong reputation for delivering outstanding medical communications. For more information, see https://www.pharmagenesis.com/healthcare-medical-services/medical-communications/
